Skip to content
value.today

Peak Processing Limited: peers

Change the peers

Peak Processing Limited beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Peak Processing Limited, Telix Pharmaceuticals Limited, Mesoblast Limited, Clinuvel Pharmaceuticals Limited, Immutep Ltd, Opthea Limited: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Peak Processing Limited, Telix Pharmaceuticals Limited, Mesoblast Limited, Clinuvel Pharmaceuticals Limited, Immutep Ltd, Opthea Limited, Incannex Healthcare Inc., Propanc Biopharma, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasurePeak Processing Limitedbase
PKP.AX · 🇦🇺 AU
Percentile in Healthcare
Percentile in Australia
Telix Pharmaceuticals Limited
TLX.AX · 🇦🇺 AU
Percentile in Healthcare
Percentile in Australia
Mesoblast Limited
MSB.AX · 🇦🇺 AU
Percentile in Healthcare
Percentile in Australia
Clinuvel Pharmaceuticals Limited
CUV.AX · 🇦🇺 AU
Percentile in Healthcare
Percentile in Australia
Immutep Ltd
IMMP · 🇦🇺 AU
Percentile in Healthcare
Percentile in Australia
Opthea Limited
OPT.AX · 🇦🇺 AU
Percentile in Healthcare
Percentile in Australia
Incannex Healthcare Inc.
IXHL · 🇦🇺 AU
Percentile in Healthcare
Percentile in Australia
Propanc Biopharma, Inc.
PPCB · 🇦🇺 AU
Percentile in Healthcare
Percentile in Australia
Group median
Size
Market cap (Better neither way: ranked highest first)——$3.8 BAug 1, 2026 · Market data1st of 7$169 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one4th of 7$538 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one2nd of 7$56 MAug 1, 2026 · Market data5th of 7$277 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 7$32 MOct 30, 2026 · Market data6th of 7$13 MOct 29, 2026 · Market data7th of 7$169 M7 ranked
Revenue (Better neither way: ranked highest first)——$804 MFY2025 · SEC1st of 4$17 MFY2025 · SEC3rd of 4$64 MFY2026 · SEC2nd of 4$7 MFY2025 · SEC4th of 4——————$41 M4 ranked
Net income (Higher is better)——$-7 MFY2025 · SEC2nd of 7$-102 MFY2025 · SEC6th of 7$23 MFY2026 · SEC1st of 7$-40 MFY2025 · SEC5th of 7$-163 MFY2025 · SEC7th of 7$-19 MFY2026 · SEC4th of 7$-19 MFY2026 · SEC3rd of 7$-19 M7 ranked
Growth
Revenue growth (Higher is better)————+55.5%FY2025 · SEC2nd of 486th78th+191.5%FY2025 · SEC1st of 496th97th+5.2%FY2026 · SEC4th of 438th41st+30.2%FY2025 · SEC3rd of 477th66th————————————+42.8%4 ranked
Revenue growth, 3 years a year (Higher is better)————+93.5%FY2025 · SEC1st of 395th86th+19.0%FY2025 · SEC2nd of 371st41st————+10.9%FY2025 · SEC3rd of 356th32nd————————————+19.0%3 ranked
Earnings per share growth (Higher is better)————————————0.0%FY2026 · SEConly one with it37th—————————————————0.0%—
Margins and returns
Gross margin (Higher is better)————53.0%FY2025 · SEC3rd of 340th—70.2%FY2025 · SEC2nd of 368th—82.9%FY2026 · SEC1st of 384th—————————————————70.2%3 ranked
Operating margin (Higher is better)————3.7%FY2025 · SEC2nd of 263rd—————43.4%FY2026 · SEC1st of 298th—————————————————23.6%2 ranked
Net margin (Higher is better)————-0.9%FY2025 · SEC2nd of 459th54th-593.8%FY2025 · SEC3rd of 44th12th36.0%FY2026 · SEC1st of 497th96th-594.8%FY2025 · SEC4th of 44th4th————————————-297.4%4 ranked
Free cash flow margin (Higher is better)————-5.3%FY2025 · SEC2nd of 444th35th-294.4%FY2025 · SEC3rd of 411th15th18.4%FY2026 · SEC1st of 486th85th-601.2%FY2025 · SEC4th of 44th5th————————————-149.9%4 ranked
Return on equity (Higher is better)————-1.9%FY2025 · SEC2nd of 671st68th-18.9%FY2025 · SEC3rd of 661st48th13.4%FY2026 · SEC1st of 685th88th-36.2%FY2025 · SEC4th of 651st42nd————-47.8%FY2026 · SEC5th of 644th38th-161.8%FY2026 · SEC6th of 615th2nd-27.6%6 ranked
Valuation
Price to sales (Better neither way: ranked highest first)————4.7×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————————8.4×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price——————————————
Price to book (Better neither way: ranked highest first)————9.2×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————————0.6×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————0.5×price Oct 30, 2026 · Market data2nd of 27th—1.4×price Oct 29, 2026 · Market data1st of 228th—0.9×2 ranked
Free cash flow yield (Higher is better)————-1.1%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————————-71.8%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————-39.8%price Oct 30, 2026 · Market data1st of 222nd—-42.5%price Oct 29, 2026 · Market data2nd of 221st—-41.1%2 ranked
Financial strength
Debt to equity (Lower is better)————0.9×FY2025 · SEC2nd of 275th—0.1×FY2025 · SEC1st of 221st—————————————————————0.5×2 ranked
Interest cover (Higher is better)————————————————————————————-42.3×FY2026 · SEConly one with it23rd—-42.3×—
Piotroski F-score (Higher is better)————5 of 9FY2025 · SEConly one with it——————————5.0 of 9—
Scorecard
Scorecard (Higher is better)——6 of 10FY2025 · Scorecard2nd of 76 of 14FY2025 · Scorecard3rd of 79 of 11FY2026 · Scorecard1st of 73 of 12FY2025 · Scorecard4th of 70 of 7FY2025 · Scorecard7th of 73 of 12FY2026 · Scorecard4th of 72 of 12FY2026 · Scorecard6th of 725% passed7 ranked
Valuation checks (Higher is better)————————————1 of 4FY2026 · Scorecard1st of 21 of 4FY2026 · Scorecard1st of 225% passed2 ranked
Growth checks (Higher is better)——3 of 4FY2025 · Scorecard1st of 73 of 6FY2025 · Scorecard2nd of 71 of 2FY2026 · Scorecard2nd of 72 of 6FY2025 · Scorecard4th of 70 of 2FY2025 · Scorecard5th of 70 of 2FY2026 · Scorecard5th of 70 of 2FY2026 · Scorecard5th of 733% passed7 ranked
Profitability checks (Higher is better)——2 of 4FY2025 · Scorecard2nd of 70 of 3FY2025 · Scorecard3rd of 72 of 3FY2026 · Scorecard1st of 70 of 3FY2025 · Scorecard3rd of 70 of 2FY2025 · Scorecard3rd of 70 of 2FY2026 · Scorecard3rd of 70 of 3FY2026 · Scorecard3rd of 70% passed7 ranked
Financial health checks (Higher is better)——1 of 2FY2025 · Scorecard3rd of 73 of 4FY2025 · Scorecard2nd of 72 of 2FY2026 · Scorecard1st of 71 of 2FY2025 · Scorecard3rd of 70 of 2FY2025 · Scorecard7th of 71 of 2FY2026 · Scorecard3rd of 71 of 3FY2026 · Scorecard6th of 750% passed7 ranked
Shareholder returns checks (Higher is better)————0 of 1FY2025 · Scorecard3rd of 54 of 4FY2026 · Scorecard1st of 50 of 1FY2025 · Scorecard3rd of 50 of 1FY2025 · Scorecard3rd of 51 of 2FY2026 · Scorecard2nd of 5——0% passed5 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)——1.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 4————1.1%2026-Q2 · 13F4th of 4——4.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 41.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 41.4%4 ranked
Institutions holding (Better neither way: ranked highest first)——742026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4————252026-Q2 · 13F2nd of 4——172026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 452026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 4214 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)————————————-7.2 pp2026-Q2 against 2026-Q1 · 13Fonly one with it——-7.2 pp—
Dividends
Shareholder yield (Higher is better)————————————————————————29.0%FY2026 · SEConly one with it98th—————29.0%—
Dividend payout (Better neither way: ranked highest first)————————————7.2%FY2026 · SEConly one with it17th—————————————————7.2%—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Peak Processing Limited: How market caps are worked out; Telix Pharmaceuticals Limited: How market caps are worked out; Mesoblast Limited: How market caps are worked out; Clinuvel Pharmaceuticals Limited: How market caps are worked out; Immutep Ltd: How market caps are worked out; Opthea Limited: How market caps are worked out; Incannex Healthcare Inc.: How market caps are worked out; Propanc Biopharma, Inc.: How market caps are worked out.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Peak Processing Limited———
Telix Pharmaceuticals Limited3.7%FY2025
63rd percentile in Healthcaremedian -7.8%, 678 companies
—
Mesoblast Limited———
Clinuvel Pharmaceuticals Limited43.4%FY2026
98th percentile in Healthcaremedian -7.8%, 678 companies
—
Immutep Ltd———
Opthea Limited———
Incannex Healthcare Inc.———
Propanc Biopharma, Inc.———

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$201 M$402 M$603 M$804 M2017201820192020202120222023202420252026Telix Pharmaceuticals Limited $804 MMesoblast Limited $17 MClinuvel Pharmaceuticals Limited $64 MImmutep Ltd $7 MOpthea Limited $0 MIncannex Healthcare Inc. $0 M

Rank in the group

1st2nd3rd4th5th6th2016201720182019202020212022202320242025Telix Pharmaceuticals Limited: 1st of 4 in 2022Telix Pharmaceuticals Limited: 1st of 4 in 2023Telix Pharmaceuticals Limited: 1st of 6 in 2024Telix Pharmaceuticals Limited: 1st of 5 in 2025Telix Pharmaceuticals LimiMesoblast Limited: 1st of 2 in 2016Mesoblast Limited: 2nd of 2 in 2017Mesoblast Limited: 1st of 2 in 2018Mesoblast Limited: 1st of 3 in 2019Mesoblast Limited: 1st of 4 in 2020Mesoblast Limited: 1st of 4 in 2021Mesoblast Limited: 2nd of 4 in 2022Mesoblast Limited: 2nd of 4 in 2023Mesoblast Limited: 3rd of 6 in 2024Mesoblast Limited: 3rd of 5 in 2025Mesoblast LimitedClinuvel Pharmaceuticals Limited: 2nd of 6 in 2024Clinuvel Pharmaceuticals Limited: 2nd of 5 in 2025Clinuvel Pharmaceuticals LImmutep Ltd: 2nd of 2 in 2016Immutep Ltd: 1st of 2 in 2017Immutep Ltd: 2nd of 2 in 2018Immutep Ltd: 2nd of 3 in 2019Immutep Ltd: 2nd of 4 in 2020Immutep Ltd: 2nd of 4 in 2021Immutep Ltd: 3rd of 4 in 2022Immutep Ltd: 3rd of 4 in 2023Immutep Ltd: 4th of 6 in 2024Immutep Ltd: 4th of 5 in 2025Immutep LtdOpthea Limited: 3rd of 3 in 2019Opthea Limited: 4th of 4 in 2020Opthea Limited: 4th of 4 in 2021Opthea Limited: 4th of 4 in 2022Opthea Limited: 4th of 4 in 2023Opthea Limited: 5th of 6 in 2024Opthea LimitedIncannex Healthcare Inc.: 3rd of 4 in 2020Incannex Healthcare Inc.: 3rd of 4 in 2021Incannex Healthcare Inc.: 6th of 6 in 2024Incannex Healthcare Inc.: 5th of 5 in 2025Incannex Healthcare Inc.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearPeak Processing LimitedTelix Pharmaceuticals LimitedMesoblast LimitedClinuvel Pharmaceuticals LimitedImmutep LtdOpthea LimitedIncannex Healthcare Inc.Propanc Biopharma, Inc.
2026———$64 MSEC————
2025—$804 MSEC1st$17 MSEC3rd$61 MSEC2nd$7 MSEC4th—$0 MSEC5th—
2024—$517 MSEC1st$6 MSEC3rd$58 MSEC2nd$5 MSEC4th$0 MSEC5th$0 MSEC6th—
2023—$334 MSEC1st$8 MSEC2nd—$4 MSEC3rd$0 MSEC4th——
2022—$111 MSEC1st$10 MSEC2nd—$5 MSEC3rd$0 MSEC4th——
2021——$7 MSEC1st—$3 MSEC2nd$0 MSEC4th$2 MSEC3rd—
2020——$32 MSEC1st—$11 MSEC2nd$0 MSEC4th$1 MSEC3rd—
2019——$17 MSEC1st—$5 MSEC2nd$0 MSEC3rd——
2018——$17 MSEC1st—$6 MSEC2nd———
2017——$2 MSEC2nd—$3 MSEC1st———
2016——$43 MSEC1st—$1 MSEC2nd———

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Peak Processing Limited#

Companies of the same industry first, then the same sector, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Telix Pharmaceuticals LimitedTLX.AX · 🇦🇺 Australia
    Same sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on file
    Market cap $3.8 B (Aug 1, 2026) · revenue $804 M (year to December 2025)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    In the group
  • Mesoblast LimitedMSB.AX · 🇦🇺 Australia
    Same sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on file
    Market cap $169 M (last known, Jan 5, 2024) · revenue $17 M (year to June 2025)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    In the group
  • Clinuvel Pharmaceuticals LimitedCUV.AX · 🇦🇺 Australia
    Same sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on file
    Market cap $538 M (last known, Jan 5, 2024) · revenue $64 M (year to June 2026)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    In the group
  • Immutep LtdIMMP · 🇦🇺 Australia
    Same sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on file
    Market cap $56 M (Aug 1, 2026) · revenue $7 M (year to June 2025)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    In the group
  • Opthea LimitedOPT.AX · 🇦🇺 Australia
    Same sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on file
    Market cap $277 M (last known, Jan 5, 2024)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    In the group
  • Incannex Healthcare Inc.IXHL · 🇦🇺 Australia
    Same sector: Healthcare (Pharmaceutical) · Same country: Australia · Ratios of the last two fiscal years on file
    Market cap $32 M (Oct 30, 2026)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    In the group
  • Propanc Biopharma, Inc.PPCB · 🇦🇺 Australia
    Same sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on file
    Market cap $13 M (Oct 29, 2026)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    In the group
  • Kazia Therapeutics LimitedKZIA · 🇦🇺 Australia
    Same sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on file
    Market cap $154 M (Aug 1, 2026) · revenue $0 M (year to June 2025)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    + Add
  • Radiopharm Theranostics LimitedRAD.AX · 🇦🇺 Australia
    Same sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on file
    Market cap $23 M (last known, Jan 5, 2024) · revenue $4 M (year to June 2025)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    + Add
  • Alterity Therapeutics LimitedATHE · 🇦🇺 Australia
    Same sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on file
    Market cap $87 M (Aug 1, 2026)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    + Add
  • Immuron LtdIMRN · 🇦🇺 Australia
    Same sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on file
    Market cap $9 M (Aug 1, 2026) · revenue $5 M (year to June 2025)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    + Add
  • Anteris Technologies Global Corp.AVR · 🇦🇺 Australia
    Same sector: Healthcare · Same country: Australia · Ratios of the last two fiscal years on file
    Market cap $564 M (Oct 27, 2026) · revenue $2 M (year to December 2025)
    45 of 100 (industry or sector 25 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.